NCT07466225 2026-03-12
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Not yet recruiting
Clinical Trials
17 trialsNCT06631326 2026-01-27
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
First Hospital of China Medical University
Completed
NCT07052448 2025-07-04
The Efficacy of Sequential RT After Triple Therapy for uHCC
Fujian Provincial Hospital
Enrolling by invitation
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06602011 2024-10-15
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
Fujian Provincial Hospital
Recruiting
NCT04763408 2024-07-18
STELLAR
Eisai Inc.
Completed
NCT05717738 2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
NCT06435013 2024-05-30
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Sun Yat-sen University
Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT04428437 2023-10-05
Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors
Humanity & Health Medical Group Limited
Terminated
NCT05889949 2023-06-07
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT04008082 2022-03-08
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT03663114 2021-01-22
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT04560751 2020-09-23
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Zhejiang Cancer Hospital
Unknown
NCT04415567 2020-06-04
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Completed